DE69523154T2 - Tachykinin (nk1) rezeptor antagonisten - Google Patents
Tachykinin (nk1) rezeptor antagonistenInfo
- Publication number
- DE69523154T2 DE69523154T2 DE69523154T DE69523154T DE69523154T2 DE 69523154 T2 DE69523154 T2 DE 69523154T2 DE 69523154 T DE69523154 T DE 69523154T DE 69523154 T DE69523154 T DE 69523154T DE 69523154 T2 DE69523154 T2 DE 69523154T2
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- tachykinin
- migraine
- pain
- receptor antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25482194A | 1994-06-06 | 1994-06-06 | |
PCT/US1995/006289 WO1995033744A1 (en) | 1994-06-06 | 1995-05-18 | Tachykinin (nk1) receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69523154D1 DE69523154D1 (de) | 2001-11-15 |
DE69523154T2 true DE69523154T2 (de) | 2002-06-06 |
Family
ID=22965712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69523154T Expired - Fee Related DE69523154T2 (de) | 1994-06-06 | 1995-05-18 | Tachykinin (nk1) rezeptor antagonisten |
Country Status (14)
Country | Link |
---|---|
US (1) | US5610176A (de) |
EP (1) | EP0764163B1 (de) |
JP (1) | JPH10501228A (de) |
AT (1) | ATE206710T1 (de) |
AU (1) | AU693898B2 (de) |
CA (1) | CA2187531A1 (de) |
DE (1) | DE69523154T2 (de) |
DK (1) | DK0764163T3 (de) |
EE (1) | EE03445B1 (de) |
ES (1) | ES2165915T3 (de) |
NZ (1) | NZ287284A (de) |
PT (1) | PT764163E (de) |
WO (1) | WO1995033744A1 (de) |
ZA (1) | ZA954609B (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004494A1 (en) * | 1992-08-13 | 1994-03-03 | Warner-Lambert Company | Tachykinin antagonists |
CA2189501A1 (en) * | 1995-11-06 | 1997-05-07 | Harry R. Howard | Nk-1 receptor antagonists for the treatment of cancer |
JP2000514047A (ja) * | 1996-06-26 | 2000-10-24 | ワーナー―ランバート・コンパニー | 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用 |
US5945508A (en) * | 1996-07-23 | 1999-08-31 | Witten; Mark L. | Substance P treatment for immunostimulation |
ES2212814T3 (es) * | 1996-10-31 | 2004-08-01 | Harbor Branch Oceanographic Institution, Inc. | Uso de compuestos y composiciones antiinflamatorias neurogenicas. |
US6291501B1 (en) | 1998-02-20 | 2001-09-18 | Harbor Branch Oceanographic Institution, Inc. | Compounds and methods of use for treatment of neurogenic inflammation |
US6472418B1 (en) | 1998-12-18 | 2002-10-29 | Warner-Lambert Company | Non-peptide NK1 receptors antagonists |
EP1156054B1 (de) * | 1999-02-23 | 2004-04-14 | Ono Pharmaceutical Co., Ltd. | Medikamente, die derivate der phosphorigensäure als aktiven inhaltsstoff enthalten |
EP1394150B1 (de) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
US6372440B2 (en) | 1999-03-10 | 2002-04-16 | Magnesium Diagnostics, Inc. | Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses |
US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
JP3938689B2 (ja) | 2000-03-16 | 2007-06-27 | エフ.ホフマン−ラ ロシュ アーゲー | Ipアンタゴニストとしてのカルボン酸誘導体 |
MY130373A (en) * | 2001-10-29 | 2007-06-29 | Malesci Sas | Linear basic compounds having nk-2 antagonist activity and formulations thereof |
EP1556054A4 (de) * | 2002-05-29 | 2007-09-05 | Univ California | Antagonisierende nk1-rezeptoren hemmen den drogenmissbrauch |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
MX2007000428A (es) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina. |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
CA2615403C (en) | 2005-07-15 | 2015-06-16 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
KR20080043852A (ko) | 2005-09-23 | 2008-05-19 | 에프. 호프만-라 로슈 아게 | 신규 투여 제형 |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2109608B1 (de) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体 |
AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP2413932A4 (de) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
EP2429293B1 (de) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | KRISTALLINE FORMEN VON (S)-7-([1,2,4]TRIAZOL[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDROISOCHINOLIN UND IHRE VERWENDUNG |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
KR101485645B1 (ko) | 2009-10-14 | 2015-01-22 | 머크 샤프 앤드 돔 코포레이션 | p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도 |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制 |
HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | ***-1受体抑制剂 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3919620A1 (de) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Zusammensetzungen mit kurzer interferierender nukleinsäure (sina) |
CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
LT2925888T (lt) | 2012-11-28 | 2018-01-10 | Merck Sharp & Dohme Corp. | Vėžio gydymo kompozicijos ir būdai |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
US20210309688A1 (en) | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20220288028A1 (en) * | 2019-05-30 | 2022-09-15 | The Schepens Eye Research Institute, Inc. | A therapeutic approach for treating non-infectious ocular immunoinflammatory disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03503650A (ja) * | 1988-04-05 | 1991-08-15 | アボツト・ラボラトリーズ | Cckアンタゴニストとしてのトリプトファン誘導体 |
US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
WO1994004494A1 (en) * | 1992-08-13 | 1994-03-03 | Warner-Lambert Company | Tachykinin antagonists |
US5472978A (en) * | 1991-07-05 | 1995-12-05 | Merck Sharp & Dohme Ltd. | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
WO1993001160A1 (en) * | 1991-07-05 | 1993-01-21 | Merck Sharp & Dohme Limited | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
EP0593615B1 (de) * | 1991-07-10 | 1996-01-31 | MERCK SHARP & DOHME LTD. | Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung |
-
1995
- 1995-05-18 DK DK95920525T patent/DK0764163T3/da active
- 1995-05-18 ES ES95920525T patent/ES2165915T3/es not_active Expired - Lifetime
- 1995-05-18 EE EE9600177A patent/EE03445B1/xx not_active IP Right Cessation
- 1995-05-18 AT AT95920525T patent/ATE206710T1/de not_active IP Right Cessation
- 1995-05-18 NZ NZ287284A patent/NZ287284A/xx unknown
- 1995-05-18 EP EP95920525A patent/EP0764163B1/de not_active Expired - Lifetime
- 1995-05-18 DE DE69523154T patent/DE69523154T2/de not_active Expired - Fee Related
- 1995-05-18 WO PCT/US1995/006289 patent/WO1995033744A1/en active IP Right Grant
- 1995-05-18 JP JP8500947A patent/JPH10501228A/ja not_active Ceased
- 1995-05-18 CA CA002187531A patent/CA2187531A1/en not_active Abandoned
- 1995-05-18 PT PT95920525T patent/PT764163E/pt unknown
- 1995-05-18 AU AU25950/95A patent/AU693898B2/en not_active Ceased
- 1995-06-05 ZA ZA954609A patent/ZA954609B/xx unknown
- 1995-09-07 US US08/525,228 patent/US5610176A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU693898B2 (en) | 1998-07-09 |
ATE206710T1 (de) | 2001-10-15 |
CA2187531A1 (en) | 1995-12-14 |
ES2165915T3 (es) | 2002-04-01 |
ZA954609B (en) | 1996-01-26 |
EP0764163A1 (de) | 1997-03-26 |
PT764163E (pt) | 2002-03-28 |
DK0764163T3 (da) | 2002-02-04 |
AU2595095A (en) | 1996-01-04 |
NZ287284A (en) | 1998-10-28 |
EP0764163B1 (de) | 2001-10-10 |
EE9600177A (et) | 1997-06-16 |
EE03445B1 (et) | 2001-06-15 |
DE69523154D1 (de) | 2001-11-15 |
JPH10501228A (ja) | 1998-02-03 |
WO1995033744A1 (en) | 1995-12-14 |
US5610176A (en) | 1997-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69523154D1 (de) | Tachykinin (nk1) rezeptor antagonisten | |
DE69329712D1 (de) | Tachykinin antagonistes | |
ES2119174T3 (es) | Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas. | |
MY131442A (en) | Excitatory amino acid receptor antagonists | |
HRP950052B1 (en) | Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels | |
ATE177099T1 (de) | Diazabicyclische neurokinin antagonisten | |
MX9805032A (es) | Analogos de piperidina 4-sustituida y su uso como antagonistas del receptor de d-asparatato de n-metilo, selectivos para el subtipo. | |
IL143313A0 (en) | Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases | |
ATE297755T1 (de) | Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind | |
DE69926254D1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
EA200500173A1 (ru) | Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов | |
DE60003899D1 (de) | Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden | |
EA200300040A1 (ru) | 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов | |
EA200300954A1 (ru) | Прегабалин-лактозные конъюгаты | |
ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
DE69832302D1 (de) | Antikonvulsive und zns-aktive bis-fluoralkylamide | |
IL147953A0 (en) | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation | |
ATE369354T1 (de) | Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems | |
DE602004008796D1 (de) | VERWENDUNG VON 1,3-DIAZADIBENZOÄe,hÜ AZULENEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN FORMULIERUNGEN FÜR DIE BEHANDLUNG UND PRÄVENTION VON ERKRANKUNGEN UND STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |